• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在补体充足和C6缺陷的幼鼠中,脑膜炎球菌外膜蛋白PorA特异性抗体和B群荚膜多糖特异性抗体的保护作用。

Protection by meningococcal outer membrane protein PorA-specific antibodies and a serogroup B capsular polysaccharide-specific antibody in complement-sufficient and C6-deficient infant rats.

作者信息

Toropainen Maija, Saarinen Leena, Vidarsson Gestur, Käyhty Helena

机构信息

National Public Health Institute, Department of Vaccines, Vaccine Immunology Laboratory, Mannerheimintie 166, FIN-00300 Helsinki, Finland.

出版信息

Infect Immun. 2006 May;74(5):2803-8. doi: 10.1128/IAI.74.5.2803-2808.2006.

DOI:10.1128/IAI.74.5.2803-2808.2006
PMID:16622217
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1459742/
Abstract

The relative contributions of antibody-induced complement-mediated bacterial lysis and antibody/complement-mediated phagocytosis to host immunity against meningococcal infections are currently unclear. Further, the in vivo effector functions of antibodies may vary depending on their specificity and Fc heavy-chain isotype. In this study, a mouse immunoglobulin G2a (mIgG2a) monoclonal antibody (MN12H2) to meningococcal outer membrane protein PorA (P1.16), its human IgG subclass derivatives (hIgG1 to hIgG4), and an mIgG2a monoclonal antibody (Nmb735) to serogroup B capsular polysaccharide (B-PS) were evaluated for passive protection against meningococcal serogroup B strain 44/76-SL (B:15:P1.7,16) in an infant rat infection model. Complement component C6-deficient (PVG/c-) rats were used to assess the importance of complement-mediated bacterial lysis for protection. The PorA-specific parental mIgG2a and the hIgG1 to hIgG3 derivatives all induced efficient bactericidal activity in vitro in the presence of human or infant rat complement and augmented bacterial clearance in complement-sufficient HsdBrlHan:WIST rats, while the hIgG4 was unable to do so. In C6-deficient PVG/c- rats, lacking complement-mediated bacterial lysis, the augmentation of bacterial clearance by PorA-specific mIgG2a and hIgG1 antibodies was impaired compared to that in the syngeneic complement-sufficient PVG/c+ rat strain. This was in contrast to the case for B-PS-specific mIgG2a, which conferred similar protective activity in both rat strains. These data suggest that while anti-B-PS antibody can provide protection in the infant rats without membrane attack complex formation, the protection afforded by anti-PorA antibody is more dependent on the activation of the whole complement pathway and subsequent bacterial lysis.

摘要

目前尚不清楚抗体诱导的补体介导的细菌裂解以及抗体/补体介导的吞噬作用对宿主抗脑膜炎球菌感染免疫的相对贡献。此外,抗体的体内效应功能可能因其特异性和Fc重链亚型而异。在本研究中,针对脑膜炎球菌外膜蛋白PorA(P1.16)的小鼠免疫球蛋白G2a(mIgG2a)单克隆抗体(MN12H2)、其人IgG亚类衍生物(hIgG1至hIgG4)以及针对B群荚膜多糖(B-PS)的mIgG2a单克隆抗体(Nmb735),在幼鼠感染模型中评估了其对脑膜炎球菌B群菌株44/76-SL(B:15:P1.7,16)的被动保护作用。使用补体成分C6缺陷(PVG/c-)大鼠来评估补体介导的细菌裂解对保护作用的重要性。PorA特异性亲本mIgG2a以及hIgG1至hIgG3衍生物在人或幼鼠补体存在的情况下均能在体外诱导高效的杀菌活性,并增强补体充足的HsdBrlHan:WIST大鼠体内的细菌清除,而hIgG4则无法做到。在缺乏补体介导的细菌裂解的C6缺陷PVG/c-大鼠中,与同基因补体充足的PVG/c+大鼠品系相比,PorA特异性mIgG2a和hIgG1抗体对细菌清除的增强作用受损。这与B-PS特异性mIgG2a的情况形成对比,后者在两种大鼠品系中均具有相似的保护活性。这些数据表明,虽然抗B-PS抗体在无膜攻击复合物形成的情况下可为幼鼠提供保护,但抗PorA抗体提供的保护更依赖于整个补体途径的激活及随后的细菌裂解。

相似文献

1
Protection by meningococcal outer membrane protein PorA-specific antibodies and a serogroup B capsular polysaccharide-specific antibody in complement-sufficient and C6-deficient infant rats.在补体充足和C6缺陷的幼鼠中,脑膜炎球菌外膜蛋白PorA特异性抗体和B群荚膜多糖特异性抗体的保护作用。
Infect Immun. 2006 May;74(5):2803-8. doi: 10.1128/IAI.74.5.2803-2808.2006.
2
Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis.在幼鼠保护试验中,天然人免疫球蛋白M抗体对B群脑膜炎球菌荚膜多糖的保护作用不依赖补体介导的细菌裂解。
Infect Immun. 2005 Aug;73(8):4694-703. doi: 10.1128/IAI.73.8.4694-4703.2005.
3
Murine monoclonal antibodies to PorA of Neisseria meningitidis show reduced protective activity in vivo against B:15:P1.7,16 subtype variants in an infant rat infection model.针对脑膜炎奈瑟菌PorA的鼠单克隆抗体在幼鼠感染模型中对B:15:P1.7,16亚型变体的体内保护活性降低。
Microb Pathog. 2001 Mar;30(3):139-48. doi: 10.1006/mpat.2000.0419.
4
The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB.PorA P1.7-2,4蛋白上的VR2表位是菌株特异性B群脑膜炎球菌疫苗MeNZB引发免疫反应的主要靶点。
Clin Vaccine Immunol. 2006 Apr;13(4):486-91. doi: 10.1128/CVI.13.4.486-491.2006.
5
Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains.用源自异源脑膜炎奈瑟菌菌株制备的囊泡进行序贯免疫可引发针对B群菌株的广泛保护性血清抗体。
Infect Immun. 2002 Nov;70(11):6021-31. doi: 10.1128/IAI.70.11.6021-6031.2002.
6
Complement activation and formation of the membrane attack complex on serogroup B Neisseria meningitidis in the presence or absence of serum bactericidal activity.在有或无血清杀菌活性的情况下,B群脑膜炎奈瑟菌补体激活及膜攻击复合物的形成。
Infect Immun. 2002 Jul;70(7):3752-8. doi: 10.1128/IAI.70.7.3752-3758.2002.
7
A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge model.一种针对脑膜炎奈瑟菌的糖缀合物疫苗可在人类婴儿中诱导产生抗体,这些抗体在新生大鼠攻毒模型中能提供针对脑膜炎球菌血症的保护作用。
Infect Immun. 2002 Dec;70(12):6576-82. doi: 10.1128/IAI.70.12.6576-6582.2002.
8
Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.用单价B群脑膜炎球菌外膜囊泡疫苗免疫后的抗体亲和力及免疫球蛋白G亚型分布
Infect Immun. 2002 Feb;70(2):584-90. doi: 10.1128/IAI.70.2.584-590.2002.
9
The four mouse IgG isotypes differ extensively in bactericidal and opsonophagocytic activity when reacting with the P1.16 epitope on the outer membrane PorA protein of Neisseria meningitidis.当与脑膜炎奈瑟菌外膜孔蛋白A(PorA)上的P1.16表位发生反应时,四种小鼠IgG同种型在杀菌和调理吞噬活性方面存在广泛差异。
Scand J Immunol. 2004 Jan;59(1):34-9. doi: 10.1111/j.0300-9475.2004.01362.x.
10
Deletion of major porins from meningococcal outer membrane vesicle vaccines enhances reactivity against heterologous serogroup B Neisseria meningitidis strains.脑膜炎球菌外膜囊泡疫苗中主要孔蛋白的缺失增强了对异源 B 群脑膜炎奈瑟菌菌株的反应性。
Vaccine. 2020 Feb 28;38(10):2396-2405. doi: 10.1016/j.vaccine.2020.01.038. Epub 2020 Feb 7.

引用本文的文献

1
Complement C6 deficiency exacerbates pathophysiology after spinal cord injury.补体 C6 缺乏症加重脊髓损伤后的病理生理学改变。
Sci Rep. 2020 Nov 11;10(1):19500. doi: 10.1038/s41598-020-76441-3.
2
Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.孔蛋白 B2 抑制非人婴儿补体替代途径有助于脑膜炎奈瑟菌在婴儿鼠模型中的毒力。
Infect Immun. 2014 Jun;82(6):2574-84. doi: 10.1128/IAI.01517-14. Epub 2014 Mar 31.
3
Functional characterization and evaluation of in vitro protective efficacy of murine monoclonal antibodies BURK24 and BURK37 against Burkholderia pseudomallei.鼠单克隆抗体 BURK24 和 BURK37 对类鼻疽伯克霍尔德菌的体外保护效力的功能表征及评估
PLoS One. 2014 Mar 10;9(3):e90930. doi: 10.1371/journal.pone.0090930. eCollection 2014.
4
Helicobacter pylori HopE and HopV porins present scarce expression among clinical isolates.幽门螺杆菌 HopE 和 HopV 孔蛋白在临床分离株中表达水平较低。
World J Gastroenterol. 2010 Jan 21;16(3):320-9. doi: 10.3748/wjg.v16.i3.320.
5
Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.基于乳酸奈瑟菌外膜囊泡的候选脑膜炎球菌病疫苗的I期安全性和免疫原性研究。
Clin Vaccine Immunol. 2009 Aug;16(8):1113-20. doi: 10.1128/CVI.00118-09. Epub 2009 Jun 24.
6
Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease.补体介导的杀菌和调理活性在预防脑膜炎球菌病中的相对重要性。
Vaccine. 2009 Jun 24;27 Suppl 2(Suppl 2):B117-25. doi: 10.1016/j.vaccine.2009.04.066. Epub 2009 May 23.
7
Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity.使用人血测量疫苗诱导的血清被动保护活性的脑膜炎球菌血症体外模型。
Clin Vaccine Immunol. 2009 Jun;16(6):785-91. doi: 10.1128/CVI.00007-09. Epub 2009 Apr 1.
8
Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera.补体因子H(fH)与脑膜炎奈瑟菌的结合对人fH具有特异性,并抑制大鼠和兔血清介导的补体激活。
Infect Immun. 2009 Feb;77(2):764-9. doi: 10.1128/IAI.01191-08. Epub 2008 Dec 1.
9
Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines.两种B群脑膜炎球菌外膜囊泡疫苗联合使用的免疫原性和安全性
Clin Vaccine Immunol. 2007 Sep;14(9):1062-9. doi: 10.1128/CVI.00094-07. Epub 2007 Jul 18.

本文引用的文献

1
Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis.在幼鼠保护试验中,天然人免疫球蛋白M抗体对B群脑膜炎球菌荚膜多糖的保护作用不依赖补体介导的细菌裂解。
Infect Immun. 2005 Aug;73(8):4694-703. doi: 10.1128/IAI.73.8.4694-4703.2005.
2
Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity.在缺乏血清杀菌活性的情况下,针对C群脑膜炎奈瑟菌的自然获得性被动保护活性。
Infect Immun. 2004 Oct;72(10):5903-9. doi: 10.1128/IAI.72.10.5903-5909.2004.
3
PorA variable regions of Neisseria meningitidis.脑膜炎奈瑟菌的PorA可变区
Emerg Infect Dis. 2004 Apr;10(4):674-8. doi: 10.3201/eid1004.030247.
4
Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine.针对基因组衍生的奈瑟氏菌抗原1870的单克隆抗体的保护活性,一种脑膜炎奈瑟氏菌候选疫苗
J Immunol. 2004 May 1;172(9):5606-15. doi: 10.4049/jimmunol.172.9.5606.
5
Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity.针对基因组衍生的奈瑟氏菌抗原2132(一种脑膜炎奈瑟氏菌候选疫苗)的抗体,在缺乏补体介导的杀菌活性的情况下可提供针对菌血症的保护。
J Infect Dis. 2003 Dec 1;188(11):1730-40. doi: 10.1086/379375. Epub 2003 Nov 19.
6
Activity of human IgG and IgA subclasses in immune defense against Neisseria meningitidis serogroup B.人类IgG和IgA亚类在针对B群脑膜炎奈瑟菌免疫防御中的活性
J Immunol. 2001 May 15;166(10):6250-6. doi: 10.4049/jimmunol.166.10.6250.
7
Murine monoclonal antibodies to PorA of Neisseria meningitidis show reduced protective activity in vivo against B:15:P1.7,16 subtype variants in an infant rat infection model.针对脑膜炎奈瑟菌PorA的鼠单克隆抗体在幼鼠感染模型中对B:15:P1.7,16亚型变体的体内保护活性降低。
Microb Pathog. 2001 Mar;30(3):139-48. doi: 10.1006/mpat.2000.0419.
8
Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection.重组脑膜炎奈瑟菌转铁蛋白结合蛋白A可预防实验性脑膜炎球菌感染。
Infect Immun. 2001 Mar;69(3):1561-7. doi: 10.1128/IAI.69.3.1561-1567.2001.
9
Human opsonins induced during meningococcal disease recognize transferrin binding protein complexes.脑膜炎球菌病期间诱导产生的人类调理素可识别转铁蛋白结合蛋白复合物。
Infect Immun. 1999 Dec;67(12):6526-32. doi: 10.1128/IAI.67.12.6526-6532.1999.
10
The infant rat model adapted to evaluate human sera for protective immunity to group B meningococci.幼鼠模型适用于评估人血清对B群脑膜炎球菌的保护性免疫。
Vaccine. 1999 Jun 4;17(20-21):2677-89. doi: 10.1016/s0264-410x(99)00049-3.